GSK Plans To File Once-Weekly GLP-1 Albiglutide By Year-End
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
GSK/Human Genome Sciences’ once-weekly injectable GLP-1 agonist albiglutide succeeds in a non-inferiority study and should be filed in late 2012. But analysts critique efficacy relative to the competition and some say the diabetes drug will come to the market too late.
You may also be interested in...
Amylin’s Bydureon Approval: How Does It Sit With Novo Nordisk?
Sponsor of the leading GLP-1 agonist, Victoza, sees the launch of the long-acting competitor from Amylin as having a class-wide impact, drawing more patients to GLP-1s – and it thinks that it can stave off the once-weekly contender.
Failed Head-To-Head Study Clouds Bydureon's Commercial Future
With competitive efficacy against successful Victoza now in doubt, Bydureon will need to differentiate itself in other ways.
Rare Disease Roundtable: Dealing With Pricing Pressure
Part 2: High costs are built into the rare disease business model. Participants at a roundtable discussion led by Scrip at the J.P. Morgan Healthcare Conference talked about how much they are feeling the pressure on pricing.